Miami Herald: Stem cell infusions improved health in frail elderly, UM researchers say
October 20, 2017
Written by: BY DANIEL CHANG
There’s no miracle medicine to combat signs of aging, such as fatigue, muscle weakness and loss of balance.
But as scientists work to unlock the mysteries of why some 80-year-olds must live in nursing homes while others play tennis every week, researchers with the University of Miami’s Interdisciplinary Stem Cell Institute report they have found the beginnings of what may be the first therapeutic treatment for frailty, a common condition of aging that can lead to falls and other adverse effects.
An early stage clinical trial conducted in Miami found that elderly patients breathed easier and walked longer distances after receiving a single infusion of stem cells from young and healthy donors, according to two studies published this week in the Journals of Gerontology.
“Every human being on the planet is aging,” said Dr. Joshua Hare, founding director of UM’s stem cell institute. “What isn’t understood so well is some people are aging successfully and some people are aging poorly.”
Hare said there’s a biological difference that causes some people to become frail in their old age while others retain mobility and energy, and he believes it has to do with chronic inflammation in the body and the withering of cells and muscle tissue.
But medicine and society have largely accepted frailty as inevitable, Hare said.
“It’s easy to draw a conclusion that, ‘Oh, well, this is going to happen anyway, and some people are luckier than others,’ ” he said.
Early findings from Hare’s clinical trials may challenge those assumptions.
The first phase of Hare’s study, which involved 15 people, showed that stem cell infusions were safe for patients. A second phase, which included 30 people, found that those who received a single stem cell infusion treatment showed improved lung function and an ability to walk farther than the group that received a placebo.
“People got better early,” Hare said, “and the improvement was sustained over time.”
The average age of those participating in the clinical trials was 78, Hare said, and those who received stem cell infusions intravenously showed physical improvement at three and six months after the therapy.
For the next phase of the clinical trial, Hare said, he will recruit about 120 people. But before that, Hare said, researchers are working to establish measurable goals in collaboration with the Food and Drug Administration, which would give the final approval for the therapy to be used broadly.
Walking distance is one of the measurable goals, and researchers already reported that elderly subjects in the clinical trials were able to walk 60 to 70 meters farther during a six-minute period after receiving the infusions.
Another measure would be to reduce inflammation biomarkers that can be found in the blood.
If the third phase of the clinical trial can show that stem cell infusions reduce those biomarkers for inflammation, Hare said, the therapy is more likely to win FDA approval.
Hare said the third phase of the clinical trial will be funded by Longeveron, a Miami company that he founded in 2014, and that has licensed the technology for the stem cell infusion therapy. The first two phases of the clinical trial were sponsored by UM.
“You need a commercial entity to do this,” Hare said. “It’s very difficult for a university to take on that level of responsibility.”
Longeveron will manufacture the stem cell infusion therapy and distribute it if the FDA approves the drug for human use, said Hare, who disclosed his ownership stake in the company as conflict of interest in the Journals of Gerontology.
Academic researchers with financial interests in the drugs they are studying is fairly common, said William Allen, a medical ethicist with the University of Florida’s College of Medicine.
“It doesn’t mean that there’s no potential for problems,” Allen said. “But lots of places do this. It’s about disclosure and how you manage the conflict.”
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron () is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
SOURCE Longeveron LLC